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of cortical plaque severity
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Alzheimer’s disease (AD) is the most common neurodegenerative disease and the leading cause of dementia. In
addition to grey matter pathology, white matter changes are now recognized as an important pathological feature
in the emergence of the disease. Despite growing recognition of the importance of white matter abnormalities in
the pathogenesis of AD, the causes of white matter degeneration are still unknown. While multiple studies propose
Wallerian-like degeneration as the source of white matter change, others suggest that primary white matter
pathology may be due, at least in part, to other mechanisms, including local effects of toxic Aβ peptides. In the
current study, we investigated levels of soluble amyloid-beta (Aβ) in white matter of AD patients (n=12) compared
with controls (n=10). Fresh frozen white matter samples were obtained from anterior (Brodmann area 9) and
posterior (Brodmann area 1, 2 and 3) areas of post-mortem AD and control brains. ELISA was used to examine levels
of soluble Aβ -42 and Aβ -40. Total cortical neuritic plaque severity rating was derived from individual ratings in the
following areas of cortex: mid-frontal, superior temporal, pre-central, inferior parietal, hippocampus (CA1), subiculum,
entorhinal cortex, transentorhinal cortex, inferior temporal, amygdala and basal forebrain. Compared with controls,
AD samples had higher white matter levels of both soluble Aβ -42 and Aβ -40. While no regional white matter
differences were found in Aβ -40, Aβ -42 levels were higher in anterior regions than in posterior regions across both
groups. After statistically controlling for total cortical neuritic plaque severity, differences in both soluble Aβ -42 and
Aβ -40 between the groups remained, suggesting that white matter Aβ peptides accumulate independent of
overall grey matter fibrillar amyloid pathology and are not simply a reflection of overall amyloid burden. These
results shed light on one potential mechanism through which white matter degeneration may occur in AD. Given
that white matter degeneration may be an early marker of disease, preceding grey matter atrophy, understanding
the mechanisms and risk factors that may lead to white matter loss could help to identify those at high risk and to
intervene earlier in the pathogenic process.
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Table 1 Demographic data
AD (n=12) Non-AD controls (n=10)
Age, years, mean (SD) 89.00 (10.43) 81.00 (7.70)
Male, % 25% 50%
Black, % 8.33% 20%
Hispanic, % 33.33% 30%
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Alzheimer’s disease (AD) is the most common neuro-
degenerative disease and the leading cause of dementia
[1]. Pathologically, AD is characterized by neuronal loss,
amyloid-beta (Aβ) plaques, composed of aggregations of
amyloid peptides, and neurofibrillary tangles (NFT), con-
sisting of hyperphosphorylated tau protein. The “amyloid
cascade hypothesis”, currently the prevailing hypothesis
regarding AD pathogenesis, states that Aβ-42 peptides ag-
gregate to form toxic Aβ-42 oligomers and plaques, which
then trigger a cascade of neuropathological events, in-
cluding neuroinflammation, oxidative stress, tau hy-
perphosphorylation and NFT formation, and, ultimately,
widespread neurodegeneration and dementia [2].
Although AD has traditionally been considered a disease
of the grey matter, in recent years, white matter changes
have come to be recognized as an important pathological
feature [3,4]. Using structural magnetic resonance imaging
(MRI), both white matter atrophy [5-8] and white matter
lesions that appear as areas of white matter hyperintensity
(WMH) on T2-weighted magnetic resonance imaging
(MRI) sequences [9-13] have been reported in AD. At the
microstructural level, diffusion tensor imaging (DTI) stud-
ies found reductions in white matter integrity in AD pa-
tients in multiple white matter regions [3,14-22]. In
neuropathology studies, white matter abnormalities have
been found to occur in more than 50% of AD cases [23],
and include axonal defect and loss, demyelination, death
of oligodendrocytes, reactive astrocytosis and microglial
activation [23-33]. White matter abnormalities are associ-
ated with performance across a range of neuropsycho-
logical tests [34], and predict AD incidence and rate of
cognitive decline in the community [9,35-37]. Although
once thought to occur secondary to grey matter degener-
ation, recent studies demonstrated that some white matter
changes in AD may occur independently of and precede
grey matter atrophy [3,4].
Despite the growing recognition of the importance of
white matter abnormalities in the pathogenesis of AD,
the pathological basis of white matter degradation re-
mains to be elucidated. While multiple studies attributed
white matter degeneration to concomitant small vessel
disease [23,32] or Wallerian-like degeneration [4,32],
others suggest that primary white matter pathology may
be due, at least in part, to other mechanisms, including
toxic Aβ peptides [4]. To investigate this possibility fur-
ther, we measured levels of soluble Aβ-40 and Aβ-42
peptides in postmortem cerebral white matter from AD
patients and non-AD controls. We elected to measure
soluble amyloid levels as, in recent years, extensive
evidence has accumulated to suggest that it is the levels
of soluble Aβ oligomers, rather than insoluble Aβ fibrils,
that correlate with the extent of synaptic loss and the se-
verity of cognitive impairment in AD [38-44]. Given theamyloid cascade hypothesis [2] and the known increase
in Aβ in AD brains, we hypothesized that AD patients
would show increased white matter levels of soluble
Aβ-40 and Aβ-42 peptides compared with non-AD con-
trols. We also hypothesized that white matter amyloid
beta levels would still be increased in AD brains, even
after statistically controlling for cortical plaque severity,
suggesting that soluble forms of amyloid in the white
matter of AD patients may not merely be a reflection of
overall amyloid pathology, but rather could indepen-
dently contribute to the pathophysiology of the disease.
While neuropathological studies have shown that the
frontal lobes appear to be the most severely affected by
white matter abnormalities [23], we have found using
structural MRI that frank white matter damage to more
posterior areas is associated with incident AD [9,35]. Given
this disparity between pathological and imaging findings,
the current study also used tissue sections from both anter-
ior and posterior sections to investigate whether white
matter amyloid beta levels vary as a function of region.
Materials and methods
Participants and neuropathological assessment
Twenty-two cases from the New York Brain Bank at
Columbia University were included in the current study
(see Table 1 for demographic information). Twelve of
these cases were pathologically diagnosed as AD and 10
were non-AD controls. Within the control group, 3 cases
were pathologically normal, 4 were classified patholo-
gically as ischemic stroke without vascular dementia, 1
was classified with progressive supranuclear palsy, 1 with
idiopathic Parkinson’s disease and 1 with lobar atrophy
without Picks disease. Neuropathological assessment was
performed blind to clinical diagnosis and diagnosis of AD
was based on CERAD criteria [45]. Of the twelve clinical
AD patients, eight had definite AD and four had probable
AD based upon CERAD criteria [46]. Of the ten non-
Alzheimer’s controls, nine did not meet CERAD criteria
for AD and one was classified as having a low probability
of AD [46]. As these are historic cases, they have not
been re-evaluated according to the more recent National
Institute on Aging-Alzheimer’s Association (NIA-AA) cri-
teria. In addition to CERAD criteria, however, diagnosis
was confirmed by also rating each case according to the
Braak and Braak neuropathological staging criteria for
Alzheimer-related changes [47] and the recommendations
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(NIA-RI) [48]. Together, these three ratings are largely
equivalent to the more contemporary NIA-AA criteria
[49]. Within the Alzheimer’s group, the ApoE status of
nine of the twelve cases was known; of these, four had an
ε4 allele. The ApoE status of nine of the ten cases in the
non-Alzheimer’s control group was known; of these, three
had an ε4 allele.
This research was reviewed by the Chair of the
Columbia University Medical Center Institutional
Review Board, who deemed the work exempt from
further review (under 45 CFR 46) because there
was no interaction with human subjects, no interven-
tion, and private, identifiable information was not
collected.
The tissue processing procedure has been described in
detail previously [45]. Briefly, the whole fresh brain was
first examined grossly, photographed and weighed. The
brain was then divided into two halves. One half brain
was processed fresh and frozen samples banked for re-
search. The other half brain was formalin fixed proc-
essed for thorough neuropathological evaluation.
White matter dissection
For the current study, fresh frozen tissue blocks from
Brodmann area (BA) 1, 2, and 3 (primary somatosensory
cortex, posterior sections) and BA9 (dorso-lateral pre-
frontal cortex, anterior sections) were utilized. White
matter was manually dissected from each block on dry
ice to prevent thawing of the tissue and frozen at −80°C
until biochemical analysis.
Analysis of amyloid levels
White matter samples (2 g each) were homogenized via
sonication on ice in 880 μL of tissue lysate buffer
(20 mM Tris–HCl (pH 7.4), 1 mM EDTA, 1 mM ethyle-
neglycoltetraacetic acid, 250 mM sucrose) supplemented
with protease inhibitors (Roche). The tissue homoge-
nates were treated with diethanolamine to extract sol-
uble Aβ and centrifuged at 100,000 × g for 60 minutes
at 4°C. The definition of soluble versus insoluble Aβ was
the same as that used in previous studies [40,50]: that is,
molecules that remain in the aqueous supernatant after
centrifugation for 1 hour are considered soluble Aβ,
while those Aβ aggregates that remain in the pellet are
considered as insoluble Aβ. The supernatant was col-
lected, total protein concentration was determined by a
BCA protein assay (Thermo Scientific) and homogenate
concentrations were standardized. Aβ-40 levels were
determined using the Aβ-40 Type II ELISA kit from
Wako (Catalog Number: 292–64701). Aβ-42 levels were
measured using the Aβ-42 High Sensitivity ELISA kit
from Wako (Catalog number: 292–64501). These kits
have been extensively validated in previous studies(e.g. [51-55]) and are known to show extremely high
sensitivity and reproducibility [54]. Both ELISA assays
were performed in accordance with the manufacturer’s
protocol, and all samples were run in duplicate. Optical
density values were measured at 450 nm using a micro-
plate reader, and then converted to concentrations
(pmol/L) based on a standard curve. For cortical amyl-
oid plaque ratings, a trained pathologist examined indi-
vidual tissue sections and the number of Aβ plaques was
manually counted. Neuritic plaque severity was rated in
one section of each of the following areas from the fixed
hemisphere: mid-frontal, superior temporal, pre-central,
inferior parietal, hippocampus (CA1), subiculum, ento-
rhinal cortex, transentorhinal cortex, inferior temporal,
amygdala and basal forebrain. For each cortical area, a
neuropathologist scanned the cortex over the entire
slide, picked the most involved area, and then counted
neuritic plaques stained with a Bielschowsky stain using
the 10x ocular and 10x objective lenses. Each cortical re-
gion received a severity rating based on the following: 1,
if there were less than 5 neuritic plaques, 2, if the num-
ber of neuritic plaques was between 5 and 15 and 3, if
there were more than 15 neuritic plaques. We derived
the total cortical neuritic plaque severity rating from the
individual rating of each cortical region as follows: 1, if
the total neuritic plaque rating was mild (i.e. the major-
ity of cortical areas contained fewer than 5 Aβ plaques),
2, if the total neuritic plaque rating was moderate
(i.e. the majority of cortical areas contained between 5
and 15 Aβ plaques) and 3, if the total neuritic plaque
rating was severe (i.e. the majority of cortical areas con-
tained more than 15 Aβ plaques). White matter tissue
immunostained with Aβ antibodies from each case in-
cluded in the study was also examined for the presence
of white matter neuritic plaques, but none were found in
any section.
Data analysis
Data were first analyzed with a repeated measures analysis
of variance (ANOVA), with Region (2 levels: Anterior,
posterior) as a within-subjects variable and Group (2
levels: AD, control) as a between-subjects variable. Two
separate ANOVAs were conducted for Aβ-40 levels and
Aβ-42 levels. Age at death was included as a covariate. In
order to investigate further the effect of region, the non-
parametric Wilcoxon signed rank sum test was used. To
study the relationship between white matter Aβ levels and
cortical plaque burden, Pearson correlations were calcu-
lated between white matter Aβ levels and neuritic plaque
severity rating in several cortical areas. To investigate
whether white matter levels of soluble Aβ were different
between AD cases and non-AD controls, independent of
cortical plaque pathology, a measure of total cortical neu-
ritic plaque severity was included as a covariate and each
Collins-Praino et al. Acta Neuropathologica Communications 2014, 2:83 Page 4 of 10
http://www.actaneurocomms.org/content/2/1/83ANOVA was re-run to test if the effect of either Group




AD patients had higher average white matter Aβ-40
levels than non-AD controls (main effect of Group:
F(1,15) = 6.338, p = 0.024; Figure 1A). Aβ-40 levels did
not differ between anterior and posterior white matter
regions in either the overall ANOVA (main effect of
Region: F(1,15) = 0.718, p = 0.410; Figure 2A) or when
the regional effect was further probed using a WilcoxonFigure 1 Main effect of group. (A) Average Aβ-40 levels were higher in t
(B) Aβ-42 levels were significantly higher in the white matter of AD patiensigned-ranks test (Z = −0.675, p = 0.500). There was
not an interaction between group and region (Group x
Region interaction: F(1,15) = 0.003, p = 0.957). No sig-
nificant correlations were found between either anterior
or posterior white matter levels of Aβ-40 and neuritic
plaque severity rating in any cortical region (Table 2).
After statistically controlling for total cortical neuritic
plaque severity, Alzheimer’s patients still had higher aver-
age white matter Aβ-40 levels than non-Alzheimer’s con-
trols (main effect of Group: F(1,14) = 6.312, p = 0.025).
After statistically controlling for total cortical neuritic
plaque severity, there was still neither a main effect of
region (F(1,14) = 0.940, p = 0.349) nor an interactionhe white matter of AD patients compared with non-AD controls.
ts compared with non-AD controls.
Figure 2 Main effect of region. (A) Aβ-40 levels were not significantly different in anterior or posterior regions of white matter. (B) There was a
trend for Aβ-42 levels to be increased in anterior regions of white matter compared to posterior regions.
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F(1,14) = 0.141, p = 0.713).
Aβ-42 levels
Compared with non-AD controls, AD patients had
higher average levels of Aβ-42 (main effect of Group:
F(1,15) = 8.024, p = 0.013; Figure 1B). While Aβ-42 levels
were not different in anterior and posterior white matter
regions (main effect of Region: F(1,15) = 1.001, p = 0.333;
Figure 2B), there was a trend for them to be higher in ante-
rior than in posterior regions (anterior: M = 45.84 pmol/L,
SD = 46.06 pmol/L; posterior: M = 27.56 pmol/L,
SD = 37.03 pmol/L). This effect was further examinedusing a Wilcoxon signed-ranks test, which demonstrated
that Aβ-42 levels were significantly higher in anterior
regions compared with posterior regions (Z = −2.243,
p = 0.025). There was not a significant interaction
between group and region (Group x Region interaction:
F(1,15) = 2.246, p = 0.155). Significant positive correla-
tions were found between anterior white matter levels of
Aβ-42 and neuritic plaque severity rating in the mid-
frontal cortex, pre-central cortex, inferior parietal cortex,
hippocampal CA1, subiculum, entorhinal cortex, transen-
torhinal cortex, inferior temporal cortex, the amygdala
and the basal forebrain (Table 2). Posterior white matter
levels of Aβ-42 were positively correlated with neuritic
Table 2 Correlations between white matter Aβ 40/42 levels (Anterior and posterior) and plaque severity rating,
assayed by CERAD criteria, in several CNS regions
Ant. Aβ-40 Post. Aβ-40 Ant. Aβ-42 Post. Aβ-42
r p r p r p r p
Mid-frontal 0.294 0.196 0.204 0.403 0.697 <0.001 0.630 0.004
Superior temporal -0.263 0.529 0.194 0.617 0.607 0.111 0.706 0.034
Pre-central 0.042 0.862 0.244 0.329 0.497 0.026 0.413 0.087
Inferior Parietal 0.351 0.118 0.228 0.347 0.744 <0.001 0.633 0.004
Hipp-CA1 0.019 0.937 0.082 0.746 0.618 0.004 0.596 0.009
Subiculum 0.282 0.228 0.347 0.159 0.457 0.043 0.448 0.062
Entorhinal 0.227 0.336 0.348 0.158 0.478 0.033 0.498 0.035
Transentorhinal 0.220 0.352 0.349 0.155 0.565 0.009 0.584 0.011
Inferior Temporal 0.270 0.250 0.298 0.230 0.653 0.002 0.655 0.003
Amygdala 0.365 0.103 0.132 0.591 0.618 0.003 0.482 0.037
Basal forebrain 0.360 0.109 -.024 0.922 0.442 0.045 0.169 0.488
Note: Significant correlations are indicated by bolded text.
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temporal cortex, inferior parietal cortex, hippocampal
CA1, entorhinal cortex, transentorhinal cortex, inferior
temporal cortex and the amygdala (Table 2). After statisti-
cally controlling for total cortical neuritic plaque severity,
average white matter Aβ-42 levels were still higher in AD
patients than in non-AD controls (main effect of Group: F
(1,14) = 5.184, p = 0.039). There was still neither a main
effect of region (F(1,14) = 1.513, p = 0.239) nor an inter-
action between group and region (Group x Region inter-
action: F(1,14) = 3.237, p = 0.094) after controlling for
total cortical neuritic plaque severity.
Discussion
The current study investigated whether levels of sol-
uble Aβ peptide are increased in the white matter of
AD patients compared with non-AD controls. Levels
of both soluble Aβ-40 and Aβ-42 were higher in the
white matter of AD patients, even after statistically
controlling for cortical neuritic plaque severity.
While no regional white matter differences were
found in Aβ -40, Aβ -42 levels were higher in ante-
rior regions than in posterior regions across both
subject groups.
The finding that soluble Aβ-40 and Aβ-42 levels are
increased in the white matter of AD patients is consis-
tent with the hypothesis that the white matter degene-
ration seen in AD could be due, in part, to the toxicity
of Aβ peptides [4]. A recent study by Horiuchi and
colleagues found that soluble Aβ at 10 μM or higher
reduced the survival of mature oligodendrocytes and
affected myelin sheet formation in vitro [56]. Similarly,
Roher and colleagues demonstrated that increased levels
of Aβ peptides are associated with reductions in multiple
myelin biochemical markers and axonal demyelination[57]. In a triple transgenic mouse model, Aβ-42 led to
loss of myelin integrity and increased apoptotic cell
death of mouse oligodendrocyte precursor cells in vitro,
an effect that was reversed through the use of a viral
vector-conjugated Aβ-42 specific intracellular antibody
[58]. Amyloid beta may have detrimental effects on
white matter via oxidative stress and the activation of
transcription factors, such as NF-κB and AP-1, which
may cause tissue damage through a pro-inflammatory
reaction [59]. Amyloid beta peptide may also activate
neutral sphingomyelinase, leading to increases in the
apoptogenic mediator ceramide [60].
The current study found significant correlations
between Aβ42 levels and neuritic plaque severity ratings
in several cortical regions. Given the amyloid cascade
hypothesis and the large increases in Aβ42 known to
occur in AD [2,38], this relationship is not surprising.
Aβ42 is the predominant form of Aβ in parenchymal
plaques [53,54] and Aβ42 displays enhanced neuro-
toxicity compared to Aβ40 [61-63]. Additionally, Aβ42 is
known to form fibrils faster than Aβ40 [64]. While Aβ40
exists as monomers, dimers, trimers and tetramers in
rapid equilibrium, Aβ42 preferentially forms pentamer
and hexamer units, which assemble into higher-order
oligomers and early protofibrils [65,66]. Hence, it was
not unexpected that white matter Aβ42 levels would be
related to the severity of cortical plaque pathology. It is
noteworthy, however, that levels of Aβ-40 and Aβ-42
were increased in AD patients compared with non-AD
controls, even after statistically controlling for cortical
neuritic plaque severity, indicating that white matter
levels of Aβ are higher in AD patients than non-AD
controls, above and beyond cortical plaque pathology.
These observations suggest that white matter Aβ pep-
tides contribute to disease pathophysiology, at least in
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vation is consistent with several recent studies that suggest
that, rather than being secondary to grey matter de-
generation (i.e. Wallerian-like degeneration), white matter
structural changes in AD might precede the emergence of
grey matter pathology [4]. Several recent neuroimaging
studies showed the presence of widespread white matter
deficits in patients with amnestic mild cognitive impair-
ment (aMCI) [67], subjective cognitive impairment [68]
and cognitively normal individuals who go on to develop
aMCI [21], despite a lack of grey matter cortical atrophy.
Neuropathological studies also indicated pathological alter-
ations in white matter preceding grey matter atrophy
[23,33]. In one neuropathological study, while widespread
white matter degeneration was observed in the brains of
preclinical AD patients, the grey matter structure was rela-
tively unaltered; conversely, the brains of patients with end-
stage AD showed both grey and white matter changes [27].
Taken together, these findings would suggest that white
matter disease might be an early event in the pathogenesis
of AD. In fact, Castano and colleagues recently hypo-
thesized that AD pathogenesis may actually begin in the
white matter with oligodendrocyte dysfunction and asso-
ciated pathological changes precipitating AD dementia and
its progression [26]. The investigation of the patho-
physiological mechanisms of white matter structural
impairments could thus be critical for the identification and
treatment of individuals at a high risk for developing AD.
In addition to the current findings, several other stu-
dies highlighted the importance of frontal lobe Aβ levels
in disease pathology. In a postmortem study of patients
with AD, Chalmers and colleagues reported that paren-
chymal amyloid load was more predictive of white mat-
ter degeneration in the frontal lobe than degenerative
vascular disease, cerebral amyloid angiopathy or APOE
ε4 genotype [69]. Similarly, postmortem studies using
antibodies to Aβ identified the frontal cortex as a loca-
tion for high amounts of amyloid deposition [70]. This
observation is consistent with [11C]-PIB PET scan stu-
dies, where the highest amount of uptake has been
observed in the frontal cortex, indicating more severe
amyloid deposition in the grey matter in this area [71]. It
is important to note, however, that PIB scans can only
reliably measure fibrillar forms of amyloid in grey matter
regions. In the current study, soluble Aβ levels were
studied exclusively in white matter tissue. Neuroimaging
studies from our group reported that it is WMH burden
in posterior regions, not the frontal lobe, that is most
predictive of incident clinical AD in the community and
of the rate of cognitive decline in AD [9,10,35]. Thus, it
is possible that, while amyloid may have a propensity to
deposit in frontal regions, it is macrostructural changes
in posterior areas that may drive the clinical presenta-
tion of the disease.One potential limitation of the current study is the
relatively heterogeneous control group. In future studies,
it would be interesting to include a larger number of
neuropathologically normal controls, in order to inves-
tigate more thoroughly how white matter pathology
differs between normal, healthy aging and AD. Another
potential limitation of the study is that the concentration
of soluble Aβ in the cortex was not measured. While it
is possible that cortical levels of soluble Aβ may be more
appropriate for direct comparison with white matter
levels of soluble Aβ, previous studies have suggested that
there is a reliable correlation between cortical levels of
soluble Aβ and both diffuse and neuritic plaques in the
cortex in AD [72,73]. Hence, in the current study, we
chose to use a rating of neuritic plaque severity as
our marker of cortical amyloid pathology. Given the
growing body of evidence that it is the levels of
soluble Aβ oligomers, rather than insoluble Aβ fibrils,
that correlate with the extent of synaptic loss and the
severity of cognitive impairment in AD [38,39,43],
however, future studies should also investigate the
correlation between cortical and white matter levels
of soluble Aβ oligomers.Conclusion
The current study found that both Aβ -42 and Aβ -40
levels were higher in the white matter of AD brains
compared with non-AD controls, even after statistically
controlling for cortical neuritic plaque severity. These
findings suggest that Aβ peptides in white matter tissue
accumulate independent of overall grey matter fibrillar
amyloid pathology and are not simply a reflection of
overall amyloid burden. Thus, white matter Aβ peptides
may contribute to disease pathophysiology, at least in
part, independent of grey matter pathology. Additionally,
while no regional white matter differences were found in
Aβ -40, Aβ -42 levels were higher in anterior regions
than in posterior regions across both subject groups.
This observation may suggest that Aβ -42 has a propen-
sity to deposit in frontal regions, although it is not yet
clear if this is related to cognitive change, or if macro-
structural changes in posterior areas, likely related to
cerebrovascular or other factors, may be more important
for the clinical presentation of the disease.
In conclusion, the results of the current study help to
shed light on a potential pathological mechanism that
may contribute to white matter abnormalities in AD.
Given that white matter change may be an early marker
of disease, preceding grey matter atrophy, understanding
the mechanisms and risk factors that may lead to white
matter damage could provide a novel mechanism by
which to identify those at high risk, allowing us to inter-
vene earlier in the pathogenic process.
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